Thursday, February 22, 2018 12:21:55 AM
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=(cognate.ASNM.+AND+bioservices.ASNM.)&OS=an/cognate+and+an/bioservices&RS=(AN/cognate+AND+AN/bioservices)
PAT. NO. Title
9,255,249 Full-Text Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
This is compared to what NWBO is listed as the assignee on:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&p=1&f=S&l=50&Query=an%2Fnorthwest+and+an%2Fbiotherapeutics&d=PTXT
PAT. NO. Title
1 9,566,294 Full-Text Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
2 9,102,917 Full-Text Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
3 8,518,636 Full-Text Tangential flow filtration devices and methods for leukocyte enrichment
4 8,409,566 Full-Text Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
5 8,389,278 Full-Text Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
6 7,790,039 Full-Text Tangential flow filtration devices and methods for stem cell enrichment
7 7,695,627 Full-Text Tangential flow filtration devices and methods for leukocyte enrichment
8 7,087,715 Full-Text Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
9 6,936,448 Full-Text Nucleic acids and proteins of a rat ganglioside GM1-specific .alpha.1-2fucosyltransferase and uses thereof
10 6,863,887 Full-Text Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
11 6,150,508 Full-Text Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
12 5,990,294 Full-Text Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, and methods of use thereof
13 5,874,290 Full-Text Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon
In addition, the USPTO currently shows the following patent applications by NWBO (admittedly, many are abandoned):
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=an%2Fnorthwest+and+an%2Fbiotherapeutics&d=PG01
PUB. APP. NO. Title
1 20170363625 QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS
2 20140072564 THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS
3 20130273654 Generation of Dendritic Cells from Monocytic Dendritic Precursor Cells with GM-CSF in the Absence of Additional Cytokines
4 20130017600 ISOLATION AND/OR PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER IMMUNOTHERAPY
5 20120252034 QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS
6 20120251561 ADMINISTRATION OF DENDRITIC CELLS PARTIALLY MATURED IN VITRO FOR THE TREATMENT OF TUMORS
7 20120244620 COMPOSITIONS AND METHODS FOR INDUCING THE ACTIVATION OF IMMATURE MONOCYTIC DENDRITIC CELLS
8 20110189150 TANGENTIAL FLOW FILTRATION DEVICES AND METHODS FOR LEUKOCYTE ENRICHMENT
9 20100062003 THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS
10 20100008892 QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS
11 20080254537 Compositions and Methods for Inducing the Activation of Immature Monocytic Dendritic Cells
12 20080254064 COMPOSITIONS AND METHODS FOR PRIMING MONOCYTIC DENDRITIC CELLS AND T CELLS FOR TH-1 RESPONSE
13 20080171023 METHOD TO INCREASE CLASS I PRESENTATION OF EXOGENOUS ANTIGENS BY HUMAN DENDRITIC CELLS
14 20060234309 Quality assays for antigen presenting cells
15 20060234286 HUMAN PARIS-1 ANTIGEN AND NUCLEIC ACIDS: DIAGNOSTIC AND THERAPEUTIC USES
16 20060057120 Administration of dendritic cells partially matured in vitro for the treatment of tumors
17 20050202019 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
18 20050189297 Tangential flow filtration devices and methods for stem cell enrichment
19 20050173315 Tangential flow filtration devices and methods for leukocyte enrichment
20 20040203143 Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
21 20040197903 Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15
22 20040024188 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM